{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:47:40Z","timestamp":1767707260483},"reference-count":61,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T00:00:00Z","timestamp":1302739200000},"content-version":"vor","delay-in-days":3300,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:p><jats:bold>Summary. <\/jats:bold> Itraconazole has become an important option in the management of invasive aspergillosis. The compound has potent and broad spectrum antifungal activity <jats:italic>in vitro<\/jats:italic> against <jats:italic>Aspergillus<\/jats:italic> spp. with a species\u2010and strain dependent fungicidal mode of action. <jats:italic>In vivo<\/jats:italic>, the antifungal efficacy of itraconazole has been demonstrated in several non\u2010immunocompromised and immunocompromised animal models of disseminated and invasive pulmonary aspergillosis. Itraconazole is available in oral and intravenous formulations, displays non\u2010linear plasma pharmacokinetics, and is usually well tolerated. Non\u2010comparative clinical data of itraconazole for therapy of suspected or proven invasive aspergillosis suggest response rates similar to those of conventional amphotericin B; however, the experience with itraconazole for induction therapy of invasive aspergillosis is limited, particularly in profoundly neutropenic patients. Itraconazole has an important role for consolidation and maintenance therapy of patients with invasive aspergillosis, and novel combination therapies involving itraconazole are currently under intensive preclinical investigation as to their usefulness for primary therapy.<\/jats:p><jats:p><jats:bold>Zusammenfassung. <\/jats:bold> Itraconazol ist zu einer wichtigen Option im Management invasiver <jats:italic>Aspergillus<\/jats:italic>\u2010Infektionen geworden. Die Substanz besitzt eine ausgepr\u00e4gte und breite antimykotische Aktivit\u00e4t gegen\u00fcber Aspergillusarten <jats:italic>in vitro<\/jats:italic> mit einem spezies\u2010 und stammabh\u00e4ngigen fungiziden Wirkmodus. <jats:italic>In vivo<\/jats:italic> ist die antimykotische Wirksamkeit von Itraconazol in mehreren nicht\u2010immunkompromittierten und immunkompromittierten Tiermodellen der disseminierten und invasiven pulmonalen Aspergillose nachgewiesen. Itraconazol steht in oraler und intraven\u00f6ser Zubereitungsform zur Verf\u00fcgung, besitzt eine nicht\u2010lineare Plasma\u2010Pharmakokinetik und ist in der Regel gut vertr\u00e4glich. Nichtvergleichende klinische Daten von Itraconazol zur Behandlung vermuteter und gesicherter invasiver <jats:italic>Aspergillus<\/jats:italic>\u2010Infektionen unterstellen Ansprechraten, die mit denen von konventionellem Amphotericin B vergleichbar sind, wobei jedoch die Erfahrungen mit Itraconazol in der Induktionstherapie insbesondere bei Patienten mit ausgepr\u00e4gter Neutropenic beschr\u00e4nkt sind. Itraconazol hat eine wichtige Rolle in der Konsolidierungs\u2010und Erhaltungstherapie von Patienten mit invasiven <jats:italic>Aspergillus<\/jats:italic>\u2010Infektionen, und neue Kombinationstherapien mit Itraconazol befinden sich derzeit unter intensiver pr\u00e4klinischer Evaluierung auf ihren Nutzen in der Prim\u00e4rtherapie.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2002.tb04770.x","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T10:39:34Z","timestamp":1302777574000},"page":"48-55","source":"Crossref","is-referenced-by-count":14,"title":["Itraconazole \u2014 perspectives for the management of invasive aspergillosis"],"prefix":"10.1111","volume":"45","author":[{"given":"A. H.","family":"Groll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/513943"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.6.749"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(96)92700-0"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60129-5"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038020-00002"},{"key":"e_1_2_1_7_2","first-page":"1158","volume-title":"Antimicrobial Chemotherapy and Vaccines","author":"Groll A.H.","year":"1998"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.4.1360-1367.2001"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1032-1037.2002"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1364"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.3.333"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.3.401"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-48-12-1087"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(98)00102-2"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.1.75"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.556-557.2002"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.12.133S.34507"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.3018"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/js950534b"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v14.i1.10"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012136608249"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.8.603.31529"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1862"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1996.tb02973.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00518.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/js960213f"},{"key":"e_1_2_1_27_2","article-title":"Package circular","author":"Sporanox\u00ae (Itraconazole) Injection.","year":"2001","journal-title":"Ortho Biotech"},{"key":"e_1_2_1_28_2","first-page":"223","volume-title":"Recent Trends in the discovery, development and evaluation of antifungal agents","author":"Heykants J.","year":"1987"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.Supplement_1.S43"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1738"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.160-165.2002"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.1.93"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401137"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.4.657"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2554-2563.2002"},{"key":"e_1_2_1_36_2","first-page":"575","volume-title":"Efficacy, safety, and pharmacokinetics of intravenous followed by oral itraconazol in patients with invasive pulmonary aspergillosis","author":"Caillot D.","year":"1999"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.4.561"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-6-200109180-00010"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90527-A"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04891-1"},{"key":"e_1_2_1_41_2","first-page":"314","volume-title":"Side effects of drugs, Annual 24, Chapter 27","author":"Groll A.H.","year":"2001"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01697985"},{"key":"e_1_2_1_43_2","first-page":"515","article-title":"Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses. Animal models","volume":"9","author":"Cutsem J.","year":"1987","journal-title":"Rev. Infect. Dis."},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2307"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3180-3183.2000"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.6.1303"},{"key":"e_1_2_1_47_2","volume-title":"Dose Escalation Pharmacodynamic Study of Intravenous Itraconazole in a Neutropenic Animal Model of Invasive Pulmonary Aspergillosis","author":"Groll A.H.","year":"2001"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1988.tb03653.x"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90475-0"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70260-O"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70263-H"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90023-X"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440370097010"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/323020"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1086\/313756"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.1907"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.6.953"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00505.x"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(98)80173-4"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1201-9712(99)90038-3"},{"key":"e_1_2_1_61_2","unstructured":"Manavathu E.K. Krishnan S. Cutright J.L.andChandresakar P.H.(2000).A comparative study of the in vitro susceptibility of Aspergillus fumigatus to antifungal agents individually and in combination by the fractional inhibitory concentration index tetrazolium reduction and radiometric assay. In Program and Abstracts of the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy: abstract 931."},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1086\/339755"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2002.tb04770.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2002.tb04770.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:24:51Z","timestamp":1700317491000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2002.tb04770.x"}},"subtitle":["Itraconazol \u2014 Perspektiven f\u00fcr das Management der invasiven Aspergillose"],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":61,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1111\/j.1439-0507.2002.tb04770.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2002.tb04770.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}